The coronavirus isn’t gone just yet. China just imposed new lockdowns in Shanghai, as the city records some of its highest numbers of new COVID-19 cases. Italy just reported another 30,710 cases on Monday, and about 59,555 on Sunday. France health authorities just said the number of hospitalized COVID-19 patients jumped to 21,073 since early February. In the U.S., experts are warning the U.S. could see another spike in cases, with some wastewater samples showing an increase in infections. According to the U.S. CDC, as noted by People, “The U.S. is also starting to see an increase of COVID-19 in wastewater samples, a strong early predictor of when the virus is about to spike. Between Feb. 24 and March 10, the presence of COVID-19 increased by 100% or more in 37% of U.S. wastewater sites, according to the Centers for Disease Control’s tracking system.” That being said, there’s still a strong need for treatments from companies, such as Revive Therapeutics (OTCQB: RVVTF) (CSE: RVV), Pfizer Inc. (NYSE: PFE), Moderna Inc. (NASDAQ: MRNA), Johnson & Johnson (NYSE: JNJ), and Merck & Co. Inc. (NYSE: MRK).

Look at Revive Therapeutics (OTCQB: RVVTF) (CSE: RVV), For Example

Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.

In collaboration with Delta Health, the Study is targeting clinicals sites operated by MLP Care, the largest hospital group in Turkey, and Istinye University with access to 30 clinical research sites and over 6000 in-patient hospital beds. As previously mentioned, the Company has selected 13 clinical research sites to complete enrollment of the Study.

The Company now expects to complete full enrollment in Q2-2022 and to also submit the Study data for 800 subjects to the data safety monitoring board to seek DSMB approval to proceed with an Emergency Use Authorization application to the Food and Drug Administration (“FDA”). The Company is preparing its regulatory package for submission to the FDA and international regulatory authorities for drug approvals.

"With the emergence of BA.2 and other possible variants coming we feel there is still a vital need for a strong anti-inflammatory and anti-oxidant oral drug to coincide with other treatments,” said Michael Frank, CEO of Revive Therapeutics.

The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.

Other related developments from around the markets include:

Pfizer Inc. announced an agreement with UNICEF to supply up to 4 million treatment courses of its COVID-19 oral treatment, PAXLOVID™ tablets and ritonavir tablets), to 95 low- and middle-income countries, pending authorization or approval. This includes all low- and lower-middle-income countries and some upper-middle-income countries in Sub-Saharan Africa as well as countries that have transitioned from lower-middle to upper-middle-income status in the last five years, accounting for approximately 53% of the world’s population.

Moderna Inc., a biotechnology company pioneering messengerRNA (mRNA) therapeutics and vaccines, announced clinical and program updates demonstrating expansion and advancement of its mRNA pipeline. This announcement reflects the Company's commitment to expanding its portfolio by building on Moderna's experience with Spikevax®, its COVID-19 vaccine. The updates include advancements in the Company's respiratory and latent virus portfolios, updates on its global health programs, and new partnerships formed in the recently launched mRNA Access program.

Johnson & Johnson announced the completion of a landmark agreement between Janssen Pharmaceuticals, Inc., and manufacturer Aspen SA Operations (Pty) Ltd, based in South Africa, to enable the first COVID-19 vaccine to be manufactured and made available by an African company for people living in Africa, with the goal of increasing COVID-19 vaccination rates across the continent. Expanding global vaccination coverage is critically important to controlling the COVID-19 pandemic and reducing the risk of emergence of new SARS-CoV-2 variants. Currently, only about 12 percent of people in Africa are fully vaccinated, which is well below the World Health Organization’s target of 70 percent population coverage for all countries.

Merck & Co. Inc. announced that the Board of Directors has declared a quarterly dividend of $0.69 per share of the company’s common stock for the second quarter of 2022. Payment will be made on April 7, 2022 to shareholders of record at the close of business on March 15, 2022.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Revive Therapeutics has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Revive Therapeutics. Please click here for full disclaimer.

Contact Information:
2818047972
[email protected]